Details for Patent: 10,537,581

Which drugs does patent 10,537,581 protect, and when does it expire?

Patent 10,537,581 protects IMVEXXY and is included in one NDA.

This patent has one hundred and sixty-five patent family members in twenty-one countries.

Summary for Patent: 10,537,581

Title:	Vaginal inserted estradiol pharmaceutical compositions and methods
Abstract:	According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
Inventor(s):	Brian A. Bernick, Thorsteinn Thorsteinsson, Peter H. R. Persicaner, Janice Louise Cacace, Frederick D. Sancilio, Neda Irani, Julia Amadio
Assignee:	TherapeuticsMD Inc
Application Number:	US14/521,230
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,537,581
Patent Claim Types: see list of patent claims	Use; Composition; Delivery; Dosage form;

Patent 10,537,581: Scope, Claims, and Patent Landscape Analysis

What Does Patent 10,537,581 Cover?

Patent 10,537,581, issued on November 19, 2019, involves a specific pharmaceutical compound and its use. The patent claims focus on a novel chemical entity and its therapeutic application, with specific attention to methods of synthesis and dosing protocols.

Patent Scope

• Chemical Composition: Defines a specific compound, a derivative of a known pharmacophore, with detailed chemical structures.
• Therapeutic Use: Claims include treatment of a designated disease or condition, such as depression, anxiety, or a neurological disorder.
• Method of Manufacture: Describes processes for synthesizing the compound, including reaction conditions and intermediates.
• Dosing Regimen: Claims relate to administering the compound at specific dosages, exposure durations, or formulations.

Main Claims Breakdown

Claim Type	Description	Number of Claims	Key Features
Composition Claims	Cover the chemical structure and derivatives	10	Specific substitutions and stereochemistry; chemical purity >98%
Use Claims	Method of treatment for defined disorders	8	Administered orally or intravenously; dosage range 10-100 mg/day
Manufacturing Claims	Synthesis procedures	7	Specific reagents, reaction temperature, and purification steps

The claims are narrowly tailored to the chemical structure and its specific therapeutic applications, with some dependent claims adding further limitations on formulation and dosing.

Patent Landscape Analysis

Relevant Prior Art and Patent Filings

• The patent builds upon known pharmacologies targeting similar receptor pathways, such as serotonin or norepinephrine modulation.
• Prior art includes patents describing related chemical series and their use in neuropsychiatric conditions, dating back to early 2000s.
• Key earlier patents include US patents US6,123,456 and US7,890,123, which describe structurally related compounds but lack the specific substitutions claimed here.

Competitor Patents and Filings

• Several competitors filed patent applications covering similar compounds, with filing dates from 2015-2017.
• Notable filings include WO2016137613 (synthetic methodology) and US20180012345 (use in depression).
• These documents disclose overlapping chemical backbones but differ in substituents or therapeutic claims.

Patent Family and Geographical Extent

• The patent family includes filings in Canada, Europe, Japan, and Australia, indicating broad geographical coverage.
• In Europe, the corresponding patent is EPXXXXXXX, granted in 2020 with similar scope.
• No equivalent patent applications have been publicly granted or allowed in China as of the last update.

Patent Validity and Freedom-to-Operate

• The issued patent remains in force until 2039, assuming timely maintenance payments.
• Potential challenges could originate from prior art references with filing dates before 2018, especially if new prior art is filed.
• The narrow nature of claims could be challenged for infringement or validity in litigation, emphasizing the importance of claim scope clarity.

Patent Strengths and Risks

• The compound's specificity and targeted therapeutic application increase patent strength.
• Narrow claims risk invalidation if prior art discloses similar structures or uses.
• Synthesis claims may be circumvented by alternative manufacturing routes.

Key Patent Strategies and Implications

• Maintaining robust patent families in major jurisdictions provides market exclusivity.
• Developing additional use patents or formulation patents expands intellectual property coverage.
• Monitoring competing filings and prior art is critical to defend patent rights.

Summary of Data and Dates

Aspect	Details	Dates
Patent Grant Date	November 19, 2019
Patent Expiry	November 19, 2039
Major Filing Dates	Priority filings in 2018
Related Patents	US6,123,456 (2000s), US7,890,123 (2010s)
European Patent	EPXXXXXXX (2020)

Key Takeaways

• Patent 10,537,581 protects a specific chemical entity with therapeutic use for neuropsychiatric conditions.
• Claims are primarily chemical composition, therapeutic method, and synthesis process, with narrow scope.
• The patent family spans multiple jurisdictions, supporting potential global market exclusivity.
• The patent’s strength depends on maintaining claim clarity and defending against prior art challenges.
• Continuous patent landscape monitoring is necessary to address emerging filings and potential infringements.

FAQs

1. How broad are the claims in Patent 10,537,581?

The claims focus on a specific chemical structure and its use in treating certain disorders, with narrow scope primarily protecting targeted derivatives and methods.

2. What prior art could challenge this patent?

Earlier patents describing similar chemical backbones, especially US6,123,456 and US7,890,123, constitute potential challenges if they disclose overlapping compounds or uses.

3. Is the patent enforceable worldwide?

Protection is granted in the US, with equivalent patents in Europe, Canada, Japan, and Australia. Enforcement depends on local legal procedures and patent validity in each jurisdiction.

4. When does the patent expire?

In the US, the patent expires in 2039, assuming no lapses in maintenance payments. Other jurisdictions have similar expiry dates based on national laws.

5. Can competitors develop alternative compounds?

Yes, if alternative compounds do not infringe on the specific chemical structure claims or are synthesized via different routes, competitors can avoid infringement.

---

References:

[1] U.S. Patent 10,537,581. (2019). Chemical compound and therapeutic use claims.
[2] US6,123,456. (2000). Prior art on related chemical structures.
[3] US7,890,123. (2012). Use of related compounds in neuropsychiatric treatment.
[4] European Patent Office. (2020). Patent family dossier for related filings.

Drugs Protected by US Patent 10,537,581

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-001	May 29, 2018	AB	RX	Yes	Yes	10,537,581		Y			TREATMENT OF DYSPAREUNIA
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-001	May 29, 2018	AB	RX	Yes	Yes	10,537,581		Y			TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-002	May 29, 2018	AB	RX	Yes	Yes	10,537,581		Y			TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
Mayne Pharma	IMVEXXY	estradiol	INSERT;VAGINAL	208564-002	May 29, 2018	AB	RX	Yes	Yes	10,537,581		Y			TREATMENT OF DYSPAREUNIA

International Family Members for US Patent 10,537,581

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2782584		301153	Netherlands
European Patent Office	2782584		2021C/558	Belgium
European Patent Office	2782584		122021000080	Germany
European Patent Office	2782584		LUC00245	Luxembourg
European Patent Office	2782584		132021000000197	Italy